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Abstract
Five-year survival rate for lung cancer is limited to 10% to 15%. Therefore, the identification of novel therapeutic
prognostic factors is an urgent requirement. The aim of this study is thus to highlight specific biomarkers in chemo-
resistant non–small cell lung cancer cell lines. Therefore, we checked—in the control condition as well as after short-
term pharmacological treatment with either docetaxel or gemcitabine—the expression of genes such as tumor
suppressor genes (CDKN2A, DAPK, FHIT, GSTP1, MGMT, RARβ2, RASSF1A, and TIMP3), genes associated with
drug resistance (BRCA1, COX2, ERCC1, IGFBP3, RRM1, and TUBB3), and stemness-related genes (CD133, OCT4,
and SLUG) in two cellular models of squamous carcinoma (CAEP) and adenocarcinoma (RAL) of the lung originally
established. Their promoter methylation profile was also evaluated. Drug-related genes were upregulated. Cisplatin
resistance matched with high levels of BRCA1 and ERCC1 in both cell lines; docetaxel sensitivity of CAEP cells was
associated to levels of TUBB3 lower than RAL cells. Although CAEP cells were more sensitive to gemcitabine, both
cell lines showed high levels of RRM1. Stemness-related genes were downregulated in the control condition but
became upregulated in docetaxel-resistant cells, indicating the selection of a population with stemness features.
We did not find an unequivocal correspondence between gene expression and respective DNA promoter methylation
status, suggesting the involvement of additional mechanisms of gene expression regulation. These results highlight
specific biomarkers consistent with the different responses of the two cell lines to standard pharmacological treat-
ments and indicate specific molecular traits for their chemoresistance.
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Introduction
Non–small cell lung cancer (NSCLC) represents a common cause of
tumor death in industrialized countries where, despite a significant
improvement in diagnostics, surgery, and chemotherapy, the overall
5-year survival rate is in fact limited to about 10% to 15% [1,2].
The recommended treatment for these tumors is surgery, whereas
radiotherapy and chemotherapy are used for the treatment of un-
resectable or locally advanced tumors and as palliative therapies for
metastatic tumors [3]. In tumors without EGFR mutations, platinum
compounds, taxanes and gemcitabine—alone or in combination—are
the traditional drugs used in standard chemotherapy, even though
tumor resistance to these treatments is common [4].
Chemoresistance can arise from different mechanisms, such as
reduced drug uptake, increased drug efflux, drug detoxification, DNA
repair, or defective apoptosis, depending on the specific drug target. In
this respect, several studies highlight relationships among specific gene
expression, therapeutic response and tumor progression, and major
classes of drugs used in the treatment of NSCLC.
In particular, resistance to platinum compounds is mainly the con-
sequence of the overexpression of DNA repair genes, such as ERCC1
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and BRCA1 [5–7]. During taxane treatment of NSCLC, BRCA1 ex-
pression represents a marker of drug sensitivity [8,9]. However, a high
expression level of TUBB3, encoding for a member of the β-tubulin
protein family, is associated with taxane resistance in different tumors,
including NSCLCs [5–7]. Conversely, high levels of FHIT expression
were shown together with significant apoptosis in in vitro experiments
[10]. NSCLC therapy may also include the use of gemcitabine, whose
intracellular active forms interfere with DNA synthesis through com-
petition with deoxycytidine and inhibition of ribonucleotide reductase.
Therefore, high levels of expression of the subunit 1 of ribonucleotide
reductase (RRM1) are associated with increased gemcitabine resistance
in NSCLC cell lines [11].
Promoter methylation is an epigenetic event usually associated with
gene silencing, implicated in the development and differentiation and
frequently deregulated in cancer [12,13]. Several studies have identified
a pattern of promoter methylation and a corresponding gene expres-
sion profile consistent with tumor progression and response to drug
treatment either in NSCLC patients or in cell lines. Several tumor
suppressor genes (TSGs) display a hypermethylated promoter in lung
cancer, including CDKN2A, RASSF1A, RARβ2, MGMT, GSTP1,
DAPK, TIMP3, and FHIT [14–17]. Aberrant methylation of
RASSF1A, DAPK, CDKN2A, and FHIT promoters was associated
with shorter overall survival [18–21].
Evaluating gene expression and promoter methylation of specific
genes significant for monitoring NSCLC progression might thus
identify specific biomarkers that could predict disease recurrence
and help in keeping watch over therapeutic response.
In the present work, to explore this issue, we used an in vitro model
based on two NSCLC cell lines, representative of either a squamous
carcinoma (CAEP) or an adenocarcinoma (RAL) of the lung, estab-
lished and studied at the Istituto Scientifico Romagnolo per lo Studio
e la Cura dei Tumori at Meldola [22–25]. In these cells, we evaluated
the expression of genes of interest in lung cancer disease, such as a set of
TSGs (CDKN2A, DAPK, FHIT, GSTP1,MGMT, RARβ2, RASSF1A,
and TIMP3) found to be implicated in lung cancer progression and
therapeutic response [19,26–32], and a set of genes associated with
specific drug resistance (BRCA1, COX2, ERCC1, IGFBP3, RRM1,
and TUBB3) [3–5,33–36]. In addition, a set of genes expressed in cells
with stemness features (CD133, OCT4, and SLUG) [37–43] was also
monitored, as increasing evidence points at small cancer cell popula-
tions, defined as cancer stem cells, sustaining NSCLC resistance to
antitumor agents [39,44,45] and accounting for tumor recurrence [46].
To investigate the involvement of our gene panel in the process
of resistance to chemotherapy, we carried out this analysis in the
basal control condition as well as after short-term pharmacological
treatment with standard chemotherapeutic drugs.
Promoter methylation was also studied to evaluate how the ex-




The study was performed on two EGFR wild-type NSCLC cell
lines, CAEP and RAL, derived from a squamous carcinoma and an
adenocarcinoma of the lung, respectively, established and characterized
in our laboratory [22–25]. Cell lines were grown in Dulbecco’s modi-
fied Eagle’s medium/HAM F12 (1:1), supplemented with 10% FBS,
2 mM L-glutamine (PAA, Pashing, Austria), and insulin (10 mg/ml;
Sigma-Aldrich, Milan, Italy) in a humidified atmosphere of 95% air
and 5% CO2 at 37°C. Cells in the exponential growth phase were
used for all the experiments.
Drugs and Treatment
Cisplatin (Ebewe Pharma-Sandoz, Origgio, Italy), docetaxel (Sanofi-
aventis SpA, Milan, Italy), and gemcitabine (Eli Lilly Italia SpA, Sesto
Fiorentino, Italy) were aliquoted, stored at −80°C, and freshly diluted
in culture medium before each experiment.
For in vitro chemosensitivity assay, drugs were tested at scalar dilu-
tions of 1:1, 1:10, and 1:100 of plasma peak concentrations (10 μM
for cisplatin, 2 μM for docetaxel, and 40 μM for gemcitabine). To
ensure that exposure times were compatible with the half-life of
the drugs administered in a clinical setting [47–50], we analyzed the
effects after 6, 1, and 3 hours of exposure, respectively, followed by
72 hours of culture in drug-free medium.
For gene expression and DNA methylation analysis, cells were
treated at either 50% inhibiting concentration (IC50) or plasma peak
concentration dosage when IC50 was not reached. These values were
0.09 μM and 2 μM docetaxel and 1.98 μM and 40 μM gemcitabine,
for, respectively, CAEP and RAL.
In Vitro Chemosensitivity Assay
Cell viability was evaluated with the sulforodamine B (SRB) assay
according to Skehan et al. [51]. Experiments were run in octoplets,
and each experiment was repeated twice. Dose-response curves were
created by Excel Software and the IC50 values were determined from
the plots.
Gene Expression Analysis
The analysis of gene expression was performed as reported by
Arienti et al. [52] using a real-time reverse transcription–polymerase
chain reaction (PCR) method. The amount of mRNA of each gene
was normalized to the endogenous references β2-microglobulin using
Gene Expression Macro Software (version 1.1; Bio-Rad Laboratories
S.r.l., Segrate (MI), Italy). Commercial control RNA, derived from a
normal lung, was used as calibrator (MPV total RNA; Stratagene,
Agilent Technologies Italia SpA, Cernusco, Italy). Primers for mRNA
amplification were designed using Beacon Designer Software (version 4;
PREMIER Biosoft International, Palo Alto, CA); sequences and
annealing temperatures are available upon request.
DNA Methylation Analysis
Promoter methylation was analyzed by a standard methylation-
specific PCR (MSP) protocol from DNA extracted in phenol-chloroform.
Briefly, 1 μg of purified DNA was subjected to bisulfite treatment
(EZ DNAMethylation Kit; Zymo Research, Irvine, CA). The methyl-
ation status of the gene promoter was determined by MSP [53] and
confirmed in two independent experiments. Total volume for MSP re-
action was 15 μl, with 4 mM MgCl2, 0.5 mM each dNTP, 0.2 μM
each primer, 0.5 U of @Taq Hot Start Thermostable DNA poly-
merase (EuroClone, Pero, Italy), and 1 μl of bisulfite-treated DNA.
Methylation of OCT4 and CD133 gene promoters was tested by bi-
sulfite sequencing, cloning PCR products in pGEM-T Easy Vector
System (Promega, Milan, Italy). Sequencing of PCR products was per-
formed using the Big Dye Terminator Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA) using the Applied Biosystems 3130 Avant
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Genetic Sequencer. Primer sequences and annealing temperatures are
available upon request.
Statistical Analysis
Gene expression of CAEP and RAL cell lines in the basal control
condition was statistically compared with two-tailed t test using
GraphPad Prism (version 4.0; GraphPad Software, San Diego, CA).
Data for basal control condition versus drug treatment expression were
statistically analyzed using one-way analysis of variance with Tukey’s
post test (GraphPad Prism, version 4.0; GraphPad Software). Differ-
ences in gene expression were considered significant for P < .05.
Results
Pharmacological Treatment
Both the investigated cell lines showed high resistance to cisplatin
treatment, even after treatment with the plasma peak concentration
(10 μM; Figure 1A).
The squamous carcinoma cells (CAEP) showed less resistance to
docetaxel and gemcitabine than the adenocarcinoma cells (RAL). In
fact, the exposure of CAEP cells to 2 μM (the plasma peak concen-
tration) docetaxel induced 80% cell death with an IC50 value of
0.09 μM (Figure 1B). When the CAEP cells were treated with gem-
citabine, an IC50 of 1.98 μM was observed with an overall survival
of about 36% at the highest dose tested (Figure 1C ). Conversely,
after either docetaxel or gemcitabine exposure, IC50 values were never
reached even at the highest concentrations tested, for the adeno-
carcinoma cells (RAL; Figure 1, B and C ).
Gene Expression Profile
Among the investigated TSGs, only the CDKN2A mRNA was
highly upregulated in both lung cancer cell lines with respect to nor-
mal lung tissue. MGMT transcript levels were upregulated (five-fold)
in RAL but not in CAEP cells. Although similar to normal lung tissue
levels, DAPK and FHIT expression in RAL cells was significantly
higher (respectively about 3-fold and 11-fold; P < .01) than in CAEP
cells. No differences between CAEP and RAL were scored for GSTP1,
RARβ2, RASSF1A, and TIMP3, although in both cell lines they were
downregulated with respect to the normal lung tissue (Figure 2).
As expected, genes associated with specific drug resistance (BRCA1,
ERCC1, RRM1, and TUBB3) were significantly upregulated in both
cell lines with respect to the normal lung tissue. A significant differ-
ence in mRNA levels of RAL versus CAEP cells was scored for
COX2 (P < .01) and TUBB3 (P < .05), respectively about 20-fold
and 5-fold increases in RAL cells. The reverse was observed for
IGFBP3: It was highly upregulated (about 100-fold) in CAEP versus
RAL cells (Figure 2).
In both cell lines, CD133 and OCT4 gene products, associated with
stemness features, were downregulated, whereas SLUG gene product
was overexpressed with respect to normal lung tissue (Figure 2).
Upon treatment with docetaxel and gemcitabine, the expression of
the investigated genes showed specific differences with respect to the
basal control condition (Figure 3). Docetaxel treatment in CAEP cells
did not modify the expression of TSGs; however, the RRM1 transcript
level was significantly decreased (42%) with respect to the basal con-
trol condition (P < .05) and OCT4 expression in treated cells increased
about six-fold (P < .01; Figure 3A). RAL cells treated with docetaxel,
in contrast, showed a significantly decreased expression of the TSGs
DAPK, FHIT, MGMT, and RARβ2 (about 22%, 35%, 5%, and
30%, respectively) compared to the basal control condition (P < .05;
Figure 3B). CD133 expression was significantly decreased (20%; P <
.05), whereas SLUG mRNA level increased about five-fold (P < .05;
Figure 3B).
The only change in the expression level of the investigated genes
induced by gemcitabine in CAEP cells occurred at the TUBB3 gene,
which was downregulated (52%) with respect to the basal control
condition (P < .05; Figure 3A). In RAL cells, however, several effects
were seen, i.e., gemcitabine treatment induced decreased expression
of the TSGs DAPK, FHIT, MGMT, and RARβ2 (about 18%, 6%,
7%, and 16%, respectively), compared to the basal control condition
(P < .05; Figure 3B); only COX2 was downregulated (8%, P < .01)
among genes associated with specific drug resistance; and finally, the
mRNA level of the CD133 gene was decreased (16%) with respect to
the basal control condition (P < .01; Figure 3B).
Promoter Methylation Analysis
TSG promoter was unmethylated forDAPK, RASSF1A, and TIMP3
and partially or completely methylated for GSTP1, MGMT, and
RARβ2, in both cell lines. CDKN2A promoter was methylated
Figure 1. Cell survival of CAEP and RAL cell lines after the treatments with (A) cisplatin, (B) docetaxel, and (C) gemcitabine.
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in CAEP but unmethylated in RAL cells. Genes associated with spe-
cific drug resistance (BRCA1, COX2, ERCC1, RRM1, TUBB3) were
unmethylated in both cell lines, except for a region of TUBB3 located
at 5′ of exon 2 that was partially methylated in CAEP. The promoter of
IGFBP3 showed partial methylation in CAEP and no methylation in
RAL. When genes associated with stemness features were considered,
CD133 and OCT4 were methylated in both cell lines, whereas SLUG
was unmethylated (Figures 4 and 5 and Table 1).
Treatment with docetaxel and gemcitabine did not change the
above-described methylation profile of our lung cancer cell lines (data
not shown).
Discussion
Specific gene expression profiles may be useful for monitoring tumor
progression, predicting therapeutic response, and assessing risk of re-
lapse. With the objective of gathering information for clinical purposes,
Figure 3. Genes differentially expressed with respect to the basal control condition in (A) CAEP and (B) RAL cell lines after the treatment
with docetaxel and gemcitabine. Statistically significant differences are indicated with asterisks, *P < .05; **P < .01.
Figure 2. Gene expression profile of CAEP and RAL cell lines in the basal control condition. Expression data were normalized against
normal lung tissue. Statistically significant differences are indicated with asterisks, *P < .05; **P < .01.
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in the present work, we used two NSCLC cell lines, representative of
a squamous carcinoma (CAEP) and of an adenocarcinoma (RAL), to
explore their expression profiles in the basal control condition and
after acute treatment with standard lung cancer chemotherapeutic
drugs. As was expected considering the neoplastic nature of the cells,
both cell lines showed a low expression profile of the TSGs GSTP1,
RASSF1A, RARβ2, and TIMP3; DAPK and FHIT were downregulated
in only CAEP cells [18,54–57]. Furthermore, genes related to drug
resistance were also more widely expressed in both cell lines than in
normal lung, as one would predict from the poor efficacy of the stan-
dard chemotherapy in the treatment of NSCLCs. Both our cell lines
showed remarkable in vitro resistance to cisplatin, consistent with
high basal levels of BRCA1 and ERCC1mRNAs, as supported by other
in vitro and in vivo studies [6,8,58].
However, CAEP and RAL cells differed in their responses to the
other drugs investigated, consistent with specific patterns of gene
expression. In particular, CAEP cells were less resistant to docetaxel;
additionally, in accordance with published data [6–8], they displayed
a lower expression level of TUBB3. CAEP cells also showed more
sensitivity to gemcitabine, although a plateau in the in vitro chemo-
sensitivity assay was observed in both cell lines. The resistance of
both cell lines to plasma peak concentrations of the drug could be
Figure 4.MSP results for CAEP and RAL cell lines in basal control condition. U, unmethylation-specific reaction; M, methylation-specific
reaction; NL, normal lymphocyte DNA; IVD, in vitro methylated DNA; H2O, PCR water control.
Figure 5. Bisulfite sequencing results for CD133 and OCT4 genes in CAEP and RAL cell lines in the basal control condition. Vertical bar,
CpG site; black square, methylated clone; white square, unmethylated clone; gray square, sequence not defined.
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explained by the observed up-regulation of RRM1, a target gene of
gemcitabine action [11,59].
The difference in sensitivity to docetaxel and gemcitabine of
CAEP versus RAL is likely because of different levels of expression
of other gene products such as COX2, an important antiapoptotic
factor involved in lung carcinogenesis [60] whose expression level
was found to be associated with chemoresistance to several agents
[4]. Indeed, we found up-regulation of COX2 gene expression in the
adenocarcinoma (RAL) cells, consistent with their greater resistance to
all the drugs tested.
The recent findings of small cancer cell populations with stem cell
features, i.e., cancer stem cells, in cancers resistant to antitumor
agents [46] was the reason for investigating the level of expression of
stem-related genes, such as OCT4, CD133, and SLUG [39,43–45] in
our cell lines. Indeed, the population surviving docetaxel treatment
showed OCT4 and SLUG up-regulation, respectively, in CAEP and
RAL cells. This finding highlights the survival of a cell population with
stemness features, expected to be more aggressive and chemoresistant
according to the literature [37–39,45]. The presence of a resistant
component with self-renewing capacity in NSCLC cells is in accor-
dance with the limited survival observed in patients treated with
docetaxel as a second-line therapy [61,62].
Because epigenetic mechanisms of gene expression regulation are
gaining increasing attention in cancer pathophysiology, we evaluated
the methylation status of the promoter of the studied genes. Although
promoter methylation is usually associated with gene silencing, we
did not find unequivocal evidence of DNA methylation and corre-
sponding low mRNA levels for our entire gene panel. The hyper-
methylated status of GSTP1, RARβ2, CD133, and OCT4 promoters
correlated with the gene silencing in both cell lines (Table 1). Loss of
expression of GSTP1 and RARβ2 associated with the hypermethylated
status of their promoter regions was also shown by Chen et al. [15],
Kerr et al. [27], and Virmani et al. [55]; similarly, the lack of methyl-
ation on the promoter region of genes associated with specific drug
resistance (BRCA1, COX2, ERCC1, RRM1, and TUBB3) was in
agreement with the detection of their transcripts (Table 1). In ad-
dition, SLUG was expressed and its promoter was unmethylated, as
expected, in both cell lines (Table 1). Despite CDKN2A (in CAEP
cells) and MGMT gene promoter methylation, as also shown by other
authors [15,17,30], these genes were highly expressed in both cell
lines (Table 1). The absence of DNA methylation in the promoter
of the other genes of interest implies that different mechanism of
regulation of gene expression are involved. Genetic alterations, such
as allelic loss of chromosome arms, could be also implicated; the 3p
arm—harboring RASSF1A (3p24), RARβ2 (3p21.3), and FHIT
(3p14.2)—is indeed frequently lost in NSCLC [63,64]. The hyper-
methylated status of CD133 and OCT4 promoters is consistent with
the differentiated phenotype of our NSCLC cell lines [65,66] and is
furthermore correlated with their down-regulation in the basal control
condition.
Finally, the treatment with docetaxel and gemcitabine did not cause
variations in the promoter methylation status of either cell line. A pos-
sible explanation could be the short term of drug treatment, which
may not have been sufficient to determine a variation in the methyla-
tion profile. Further investigation, which also takes the chromatin
structure and histone modifications into account, might better describe
the mechanism involved in the modulation of gene expression.
The results reported in this work highlight specific biomarkers con-
sistent with the different responses of the two cell lines to standard
pharmacological treatment and indicate a molecular trait of their
chemoresistance. CAEP and RAL cell lines may, therefore, be consid-
ered validated models for testing novel anticancer compounds. These
cell lines may, in addition, represent a simple model for evaluating
how cell populations with stem cell features impact cancer resistance
to antitumor agents.
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